CrystalGenomics Inc
CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial. The company's drug candidates also include CG200745, a histon… Read more
CrystalGenomics Inc (083790) - Total Liabilities
Latest total liabilities as of September 2025: ₩124.24 Billion KRW
Based on the latest financial reports, CrystalGenomics Inc (083790) has total liabilities worth ₩124.24 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
CrystalGenomics Inc - Total Liabilities Trend (2011–2024)
This chart illustrates how CrystalGenomics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
CrystalGenomics Inc Competitors by Total Liabilities
The table below lists competitors of CrystalGenomics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mevaco S.A
AT:MEVA
|
Greece | €26.61 Million |
|
Media Capital
LS:MCP
|
Portugal | €98.83 Million |
|
China Fineblanking Technology Co Ltd
TWO:1586
|
Taiwan | NT$1.87 Billion |
|
AstroNova Inc
NASDAQ:ALOT
|
USA | $63.95 Million |
|
JTC Inc
KQ:950170
|
Korea | ₩168.85 Billion |
|
Humasis Co. Ltd
KQ:205470
|
Korea | ₩90.75 Billion |
|
NEBAG NA SF 0,02
F:NWR
|
Germany | €42.11K |
|
Precise Corporation Public Company Limited
BK:PCC
|
Thailand | ฿1.72 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down CrystalGenomics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.45 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.82 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.59 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CrystalGenomics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CrystalGenomics Inc (2011–2024)
The table below shows the annual total liabilities of CrystalGenomics Inc from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩161.95 Billion | +65.55% |
| 2023-12-31 | ₩97.82 Billion | -27.18% |
| 2022-12-31 | ₩134.34 Billion | +7.39% |
| 2021-12-31 | ₩125.09 Billion | +22.39% |
| 2020-12-31 | ₩102.20 Billion | -55.59% |
| 2019-12-31 | ₩230.14 Billion | +217.64% |
| 2018-12-31 | ₩72.45 Billion | +159.89% |
| 2017-12-31 | ₩27.88 Billion | -38.74% |
| 2016-12-31 | ₩45.51 Billion | -17.77% |
| 2015-12-31 | ₩55.34 Billion | +8.47% |
| 2014-12-31 | ₩51.02 Billion | -3.01% |
| 2013-12-31 | ₩52.61 Billion | +62.91% |
| 2012-12-31 | ₩32.29 Billion | -0.92% |
| 2011-12-31 | ₩32.59 Billion | -- |